C. Mills
Thank you, today a just quickly you Matt, call. mission this conference as we and exist review Starting on us for out, do, as of let's really joining why thank we Elutia, company. the always
time. implant patient's isn't own simply incorporate that or instead, tissue metal combining traditional without drug or medicine talk about a some or type and can a concept of actual therapeutics this it's we're medicine, with is become implant the so we for therapeutic, polymer So synthetic humanizing biologics and compromise. time this the about the of ever elutes thrive And plastic that that humanizing living but can so or first living patients that over talking when remodel
care every and thrive that medicine there, means of we take for customer With we is husband, word we those brother, loved our this and we realize a single a a a provide they if quality one. father, another without very there were son, that out a patients it means and out to also own. products that demographic patients also humanizing the compromise.
This do a them And can And every thing with our payload. addition market us. seriously, therapeutic recognize single sophisticated that as so And mother, that
let's investment you off should start summary a really with to you we If think in think high-level very story. why a quickly and new be we what compelling are Elutia, is interested
when active biological launch designed it's track Elutia's elution and of technology. record protect steadily and So about EluPro, we didn't a This specifically product, earlier matrix drug this the this second rifampin starting what powerful our us of deployment product, talking for January excited envelope of our selling starting this we're launch -- the about EluPro soft XXXX idea by with the we say just with deployment the are planned which very, second our envelope CanGaroo is commercial like first market. about on full to half This it And of event, an very we're and focused antibiotic-eluting in now. was quarter. on the successful have XXXX. on drug in antibiotics, and minocycline. was drug patients EluPro the EluPro in combining but only of technology. event year, really We it June talking the happened monumental EluPro, built We launch
device that's envelope challenge.
Worth pacemaker other also pacemakers market. to And pacemakers only Well, million $XXX say So like? to this for include these why implantable indications call an enough market product such $XXX deal EluPro I'll We a the defibrillators. aspects clearance noting, isn't white beyond look one neurostimulation. be uncontested. out We us million of CIED a to not eluting other the is market, competitor FDA superior for because and the is believe it the There a and big protection a fully to collectively there But have that's other me-too of received forward the is on we with we product. space for competitor. that market antibiotic the and
$X an device urinary; about fecal And So pain management; market. incontinence, additional and billion both epilepsy. apnea and talking sleep we're
is to in that one indication. size collectively So equal cardiac the
into developed EluPro more as as going lastly, that efforts bit end we like and markets are technology well.
And We talk EluPro. didn't to about exploiting biologics time. point EluPro our actively a a to platform we develop with I'd over of drug-eluting building growing those out, So we'll little
excited We'll summary that the all go that Elutia a at So a of But snapshot that. super of level. we're about is into investment more. high
internally. So and today, with it I wanted wanted -- our I we of granularity actually to more talk execute as conference we the call share -- plan about sort it as to
So these are use we internally. words the actually
company at Elutia. value the how I'm you into So plan continually take inviting to look to build of the our a on executing we're
go it we through So very methodically.
every And also that execute systems. needed.
And tremendous about to it. this the resources think sound of to not have introduce that was technology we financial all a strong, have make great And to indication but it's so Then it's position reach do order all us and that needed the do be sure in, introduce stuff have we've of then we Last on have I that to it's but product, that we quarter it solidifying it strategy. to quarter, the clearing clear can lastly, go I our it. it, The first thing position. we to had we make that kind we in we produce enough progress made reach really super this was to need got also -- to needed, can grow every to technology to this the involved that for we that patient get it hospital so financial can
of through today. So each going the going for these different be granularity. some call to this to We're is the go plan boxes in game
of category as for was it under We drug-eluting we let's monumental talked June, It, So really regulatory was off couple We the that product kick received about. with, It. were the us. for Clear world's first Clear for of approval reasons. in happy a this And BioEnvelope
shelf this asked was received One all product. the we for of of them we life that for,
life.
We prevents So like. That And and device release, patient's down received a we X-month shelf minocycline, and this has [ shelf extended you're It up that powerful the antibiotics great if migrating matrix. from wrapped the indication. in chest EluPro biological from moving out. new, received what rifampin is great primary all matrix, product, eroding standpoint, in wall looks a life a this ] again, full the
used to We in have allows it an de procedures. both novo be indication that
procedure. soon put is and pacemaker So a in, out as change as
is this--it's a response. or So others, in both a used could comes and then battery And big we've healthy allows chest it like the own reconstituted pocket. the foreign to, physicians dissolves upsize those.
Physicians perfectly wall for of picture time an and metal a really, problem, to of is tissue. a this a talked the the the from is really a really slippery is lead when lastly, HRS into change, you this over because with be easily that it this -- to This product at regenerates. just a it we sits And can't if underlying need no not have you wet, is there, instead, it's product them.
And simply not the for the absolutely product there's there pacemaker. that to and slide see love polymer, it a from patient's envelope completely patient's synthetic, lubricity remodels time. as conforms a this vascularized when it that into this But of not that hear deal kind And beautiful body
don't body foreign You a have anymore.
long term, of the that place. problem from type so completely And eliminates it in taking
about, currently an So that in rhythm realizes device that to sales, order talked super for we billion also now protect. additional billion about about to That were we be going we are and so the have primary this there's the that an claim is doing market, was in excited market after $X have were able seeking.
But that opportunity go market the $X label strategic cardiac meaning management and we implanted went billion that market. there purposes devices in as we just we we $X get and market is neurostimulation after, were everyone and device approval
describe make And so both to we these adequately. really of markets want I sure
most market cardiac rhythm we're start management. which first with for us on, the the Let's one important and is focused
Biotronik largest at is lastly, let's XX%. Boston Behind in a little bit. then This them, only primary is at we XX%. Abbott players into at the have the market has and and a that -- this to So and players X dig space. XX%; Scientific defibrillator X Medtronic pacemaker that
Medtronic is in a and Now product, a is with that eluting standpoint very competitive this line pretty fully it's a in it back introduced the they acquired sales acquired. a in interesting TYRX envelope. when actually product company And story antibiotic a was called synthetic a from TYRX XXXX, product little
acquired dissolves same product they antibiotics this the product Medtronic and it's is liberates and went good and rifampin And year dissolves, they they was between million you market And envelope them. implanting their implanted, pacemaker $XXX a after minocycline.
And Hey, right. to now And it the over defibrillator they so they we we kind idea with really this -- a million really time, this right did beautiful the what and this somewhere of it's do product. as have use, for job as space, market. into it sales able and is, -- and to this creating estimate were you're are a And guys $XXX said,
And really pouch definitively will answer derisked is eluting The this be an the marketplace they so idea; yes. to have antibiotic that around accepted.
improved can Now that product upon. think we be it's a
a that at now, at XX% And and to And of these pretty we to have love look we say is so that to have paired product. them XX% XX% look at over of physicians. fantastic.
But rifampin have dynamics minocycline, biologic least to product, again the right a with market a and this we a at that's those taken is We markets product really of, when this was because that and have really pretty great market access fully And this. favorable we've not believe you, whitespace here of all to the pouch. you from me-too a that Like we biological those do envelope does. same Medtronic's uncontested use. a over have doesn't have product good. in we those hear This TYRX market things It did if and tell product I'm that look might you superior we antibiotics this, me-too powerful that does they far all
really after we're going space. the of market excited And this rest so about
market. the Okay. cardiac That's
briefly also looking which market, is and that in market another just we billion $X We up picked what neurostimulation like. were this devices at looks
market So growing is the XX%. at neurostimulation
think these EluPro. not are And that to -- underlying And to add look but sleep So devices, in at only are you've and where apnea. procedures all believe in for of XX% to has to more major They're in and XX% we a rate. apnea of here's quite the they with underlying devices a incontinence, about we and devices the to go not healthy successful frankly, and market We both need as with compatibility really management; markets It that XX% having in. technology. X these markets. X% revisions.
These significant fecal; complication, we epilepsy sleep having it XX% rate it, the that for the technology underlying patients thing put components the put can are relates across can and value, the complication make those got patient. requiring reason, rate, urinary XX% -- rate, pain complication complication screaming
Okay.
excited so So EluPro that Clear it about finally having wraps up cleared. why we were and
we've to is next really that you product. do got am -- of let's to make just take on. Now quickly. sort in I step let got The we've move me
First, we XX,XXX facility which same operations We've we manufacture our place there units. have facility, in is had Roswell, and in EluPro the Georgia. CanGaroo, turned since out manufacture XXXX manufacturing
isn't process the able of been be doing time at is addition it increases a long manufacture to for it? to antibiotics this manufacturing it This sure complexity, been new are We've be the first but a this the we're probably a at at you you're into We've risky for while. not for So To us. this. time. going thing Like this?
clean that of a also rooms. has have has lot We a great capacity. facility really It
ability facility to $XXX rate to current and build in of of out at the doesn't lot the actually of sophisticated from manufacture So EluPro about there run whole we're a talking a million require space.
that to the get to launch will we up able expand by of the thing we beyond be will that open million comes, we and So And the in efficiently capacity going. have need capacity and revenue. and And to certainly $XXX do more have capacity. able increase we time -- be we time way, when think this
noted and were Lastly, FDA the that lasted about we the and the from something month inspection It proud inspection comprehensive, of site really in about going week. FDA inspection there, of of no June. observations an also proud FDA, a through through while went at down was a no It super whatsoever. completed I'm complete submission that group review audit was with of the deficiencies, I'm is and the team EluPro
side, health So products. the manufacture on side, a to a we approval we've of we've are health got bill got of bill and clean clean and on the ready facility
a this say entire [indiscernible] proud cheers was an this event. and And Hannah understatement. it associate also so that up talk EluPro there manufactured and first the in say, the to unit leadership of operations was I let's to in been has to parent gentlemen, Georgia our manufactured see went she I applause will team ladies is commercial super Le, monumental ever am happy senior is this for use, that and that.
This, Roswell, about facility. say
go. there so you And
underway this in cleared off first product. are right. currently of We've the on made We've expected in manufacturing and are lots QA We it. are it. review line the It's well shortly.
All
it's it Now the in systems the before, the we of and trivial, talk got and to maybe is rate-limiting we've this actually hospital have think introduction heard you hospital product about introduce into not this step. system, the me but
collateral So in we order all to the thing needed of that. first was the do
of think think can We whether new what see EluPro it. or material the be brings really very looks there, to the or a packages. for you value differentiated like. been freshness so the forward love analysis market This committee it's the that talks We years. stagnant And We with product really is and last it promotional packaging over what's this about very is it XX look consistent brand.
to active its we Well, talked significant approximately continue specificity. there talked, is so So network. as where are which we hospitals like build and we a continue hospital XXX accounts out I accounts, in the active, since CanGaroo increase we are before, market. this? out time last to this have we've new And on add the XXX about currently we
with also VAC important are hospital it's so has through one submission, to we just for though EluPro. doesn't one, because note, value We EluPro have CanGaroo, account that to they committee transfer over the and just analysis go on a mean with -- underway. process is or
have we that So completed to do you VAC. submit in that of packages the to need assembly to order
sort basis. being on that of It's So done account-by-account is done. an
going VACs. these in are the champions them physician reps at our the into in with KOLs, personally are those hand-in-hand and territories submitting Our they
first going that our prioritizing of, accounts for obviously are from to a standpoint a are we key launch. We
launch in launch of started with the has January registry year now. the quarter is full In So starts soft And clinical XXXX.
All beginning half we're product data. where to the our in a this of this of that of of second collect the conjunction right. initiation first XXXX,
without were and of about TYRX XX% where where we're gone want instead pulling their users. a wouldn't it they there. EluPro we So this envelope that market was did, basically all a XX users them or and complete would the switch through receiving that envelope of a of out I've business, users said And if be XX% having before survey This some TYRX to become reception them the biologic explaining we yes. to benefits asking of synthetic about talking
really And think physicians on hey, here. product approval. as on the so gratifying we since is thought, receiving I we about.
But reception to enthusiastic this track are this care were us that something as we We're more for that we're validating right building was the what's
important my out can hospital No we're of to industry can that How on the physician for those we is mark, But evaluating are decisions.
But treating also actually the all this how a clearly thinks industry and show I sorting if Hey, inbound to Not my that calls interested is going a the we're the product. market. for me we product text is all that thing receiving get interesting, can what of we've this? the we in that the what validating we as me in making us is the should, kinds product that's therefore, market That that super responsibly I time there, can this bring treating system? stuff, I enthusiasm. other ready way move not validating middle and about of I it night. this only can And it's night. hey, but And there exciting text very a excited very, the the it. is of partners we And We'll CIED -- into a neurostim out the the and us work are value my is responsibly -- colleagues? the that middle So industry that happening. think love understand I move hands need through physicians. the on. of How and that's to thinks this that's of by should And telling the right? launch. the get This way, you're product developed. as appreciate through
I for I I it I stay to the mean stagnant. thing mean when the do the enough it. brand, Okay. We've and value And introduce got say of mean not grow we then last grow company. -- it, the the team, to need us to is And
that now. we're right how about doing talk let's So
thing is teams. systematically methodically, are we building commercial out First our
want thing not for be intelligently. to in to team are are I and reps not reps growing, and hoping market doing EluPro We this clear now and at a comes. put we we're really I just that parenthesis this throwing XX here, indiscriminately, up the
methodically. them adding are We
contribution.
Same quality as can places significant SimpliDerm. think it are people thing adding we where have We they grows with to a
the So where the asset today. great direct on product of to we been if it one more don't haven't a that are SimpliDerm hand team make. sales can't SimpliDerm, much great have the a it's well.
We product. we about on and EluPro product, as controlling of be we the talked sales any is and investing and to But largely more it's show And a continues really do destiny stuff
BD the if going that other these sense different is on, can new they as so Operations, really lastly, going we're or leadership time oversee I solid get validates lines. arrangements the excited a and is line. and and is Ryan the sector. think, We got President And of to we that really a And starting the efforts then we're that were We that make just EluPro drug-eluting intensifying of biomatrix this we with to sudden organization.
I team, finish these he's doing talked a of of to with. have all This so these developed adjacent EluPro. first all have end, of we're towards quality Vice that guy And what get be types lot adding we markets are EluPro also for starting a spend we of partnerships for, team, adjacent a to the there really indications production is into product really as of success add Marques to to the there.
And about both that didn't going to to EluPro a to really, think see to Ryan manufacturing to out the lot have markets we, line. about develop we there.
out platform products have level, very building property make valuable. the building disproportionately do makes that And We which and think are as a intellectual broad our teams and more are a they they aggressively product also a on. robust R&D technology we the from company position, that
incredibly an Elutia. need. without all, though, do And quarter. in times that so this, be much any Couldn't of at exciting the of thank the financial really all more couldn't proud We resources successful I them team. for So we
Officer will extents some the now make to really had great it which talking solid Ferguson, Matt of can Financial through went we turn we our plan.
And we will I go position sure financial to in details. and so stop that Chief financial over a who to on And growth execute pretty this
